Quince Therapeutics S.p.a.

This Phase 3 trial tested a treatment called EryDex for people with Ataxia Telangiectasia (A-T), a rare disease that affects movement and the immune system. The study involved 105 participants who received either EryDex or a placebo every 28 days. The goal was to see if EryDex co…